News & Media

GVI Clinical Development Solutions and Guangzhou IRD Medicine Company Create Global CRO

WINNIPEG, MANITOBA – May 3, 2011 – GVI Clinical Development Solutions Inc. (CDS),
headquartered in Winnipeg, Canada and Guangzhou, China based Guangzhou IRD Medicine Company,
announce today the signing of a Memorandum of Understanding to create a joint venture company called
IRD-CDS, based in China.

IRD-CDS is committed to providing excellence in clinical development services and expertise in the
conduct of clinical trials.

“We are very pleased to have formalized our relationship with Guangzhou IRD Medicine Company
through the creation of IRD-CDS,” commented Jan-Ake Westin, President of CDS. “Their in-depth
knowledge of the life science industry in China combined with our team’s expertise in conducting global
clinical trials makes for a strong partnership that is ready to meet the needs of clinical stage companies.”

IRD-CDS’ flexibility and active participation during the critical stages of the clinical development process
make it an ideal clinical partner for life science companies who want to take advantage of the expanding
clinical trial environment in China. The CDS group has tremendous global experience in clinical research
trials and strong relationships within the industry. Current clients include world class research hospitals,
multinational and emerging life science companies.

IRD-CDS is a full service contract research organization supporting biotechnology, pharmaceutical,
diagnostic, medical device, and nutraceutical companies looking to conduct Phase II & III clinical trials in
China.

For more information please contact:
GVI Clinical Development Solutions Inc.
Jason Leibert
Business Development Manager
204-478-5601
jleibert@gvicds.com


Guangzhou IRD Medicine Company Ltd.
Dr. Liu Xin
Assistant General Manager
8620-28609020
liu.xin@hysmed.com

Back

Subscribe to the BAM Newsletter

Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.

Subscribe